Sign in
Download Opera News App

Disease-prevention-and-treatment

VBL Therapeutics Expands Ongoing OVAL Phase 3 Study On Ofranergene Obadenovec Into Europe

VBL Therapeutics Expands Ongoing OVAL Phase 3 Study On Ofranergene Obadenovec Into Europe

VBL Therapeutics (VBLT) announced Tuesday the expansion of its ongoing OVAL Phase 3 study investigating ofranergene obadenovec (VB-111), for the treatment of platinum-resistant ovarian cancer into Europe, where the first patient has now been enrolled. The study continues to actively recruit patients in the U.S. and Israel, with over 200 patients enrolled to date. VB-111 is VBL's proprietary anti-cancer gene therapy product...

Read Full Story
Data Safety Monitoring Committee Europe OVAL OVAL Phase 3 VBL VBL Therapeutics